Immunome IncIMNM
Price$20.89

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $6.9M-23.2% YoYTTM through 30 Jun 2026
Net Income -$212.4MTTM through 30 Jun 2026
Free Cash Flow -$219.1MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
Operating Margin-3,228.8%
Net Margin-3,060.0%

Returns

-38.2%ROE
-36.2%ROA

Balance Sheet Health

Debt / Equity0.01x
Current Ratio21.68x
Net Debt-$582.7Mnet cash position
Cash & Equivalents$217.7M

Quality Metrics

Altman Z-Score41.20
Piotroski F-Score2 / 9
FCF Margin-3,156.4%
Rule of 40-3,250.0
Earnings-Beat Rate0.0%

Multi-Year Trend

Revenue
'23'24'25
FY2025: $6.9M
Diluted EPS-$2.53TTM
'20'21'22'23'24'25
FY2025: $-2.43

Dividend

No dividend

Capital Allocation

R&D Spend$206.2M
Capex Intensity148.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.